Skip to main content

Table 1 Patients included in the survival analyses stratified according to IL6 diplotype (A) and rs1800795 (B)

From: IL6 genotype, tumour ER-status, and treatment predicted disease-free survival in a prospective breast cancer cohort

 

(A)

(B)

 

Patients included in the diplotype survival analyses

 

Stratified according to IL6 diplotype*

Patients included in the rs1800795 survival analyses

 

Stratified accoding to rs1800795**

   

GGGC/GGGC

AGCC/GGGC

AGCC/AGCC

Rare diplotypes

  

GG

GC

CC

 

Median (IQR***) or n (%)

Missing

Median (IQR) or n (%)

Median (IQR) or n (%)

Median (IQR) or n (%)

Median (IQR) or n (%)

Median (IQR***) or n (%)

Missing

Median (IQR) or n (%)

Median (IQR) or n (%)

Median (IQR) or n (%)

n=

567

 

130 (22.9)

221 (39.0)

131 (23.1)

85 (15.0)

574

 

181 (31.5)

257 (44.8)

136 (23.7)

Age at diagnosis, yrs

59.7 (51.8-66.3)

-

60.5 (49.2-66.7)

59.5 (51.4-66.7)

59.8 (53.8-66.4)

58.4 (51.1-65.2)

59.8 (52.0-66.4)

-

60.5 (49.9-67.1)

59.5 (52.2-66.4)

59.8 (53.8-66.3)

Weight, kgs

68.0 (61.0-76.7)

2

69.0 (62.0-81.3)

67.0 (60.0-75.0)

68.0 (61.0-78.5)

68.3 (62.0-77.6)

68.0 (61.0-76.9)

2

69.0 (61.9-80.0)

67.1 (60.4-75.0)

69.0 (61.0-78.9)

Height, m

1.66 (1.62-1.70)

1

1.66 (1.62-1.71)

1.65 (1.62-1.69)

1.65 (1.62-1.70)

1.67 (1.60-1.70)

1.66 (1.62-1.70)

1

1.66 (1.60-1.71)

1.66 (1.62-1.69)

1.66 (1.62-1.70)

BMI, kgs/m 2

24.6 (22.3-27.7)

3

25.2 (22.9-29.1)

24.3 (21.9-26.9)

24.6 (22.4-28.6)

24.4 (22.2-28.2)

24.6 (22.3-27.9)

3

25.2 (22.6-28.7)

24.4 (22.1-27.4)

24.6 (22.4-28.8)

Breast volume

1000 (600–1450)

75a

1000 (700–1538)

950 (600–1450)

988 (600–1450)

900 (585–1563)

1000 (600–1450)

75a

950 (650–1400)

1000 (625–1563)

1000 (600–1450)

Breast volume ≥850 ml

281 (57.1)

75a

68 (60.7)

110 (55.6)

65 (59.1)

38 (52.8)

286 (57.3)

75a

86 (55.8)

132 (57.4)

68 (59.1)

Waist-Hip Ratio

0.84 (0.78-0.89)

2

0.84 (0.78-0.90)

0.83 (0.78-0.88)

0.84 (0.79-0.89)

0.83 (0.78-0.89)

0.84 (0.78-0.89)

2

0.83 (0.78-0.90)

0.83 (0.78-0.88)

0.84 (0.79-0.89)

Age at menarche, yrs

13 (12–14)

3

13 (12–14)

13 (12–14)

14 (13–14)

13 (12–14)

13 (12–14)

3

13 (12–14)

13 (12–14)

14 (13–14)

Parous

485 (85.5)

-

111 (85.4)

192 (86.9)

108 (82.4)

74 (87.1)

490 (85.4)

-

156 (86.2)

222 (86.4)

112 (82.4)

Alcohol use

 

1

     

1

   

Never

62 (11.0)

 

19 (14.6)

23 (10.4)

15 (11.5)

5 (6.0)

62 (10.8)

 

23 (12.8)

24 (9.3)

15 (11.0)

Not more than once a month

149 (26.3)

 

37 (28.5)

57 (25.8)

34 (26.0)

21 (25.0)

154 (26.9)

 

48 (26.7)

69 (26.8)

37 (27.2)

2-4 times per month

216 (38.2)

 

41 (31.5)

84 (38.0)

54 (41.2)

37 (44.0)

217 (37.9)

 

64 (35.6)

97 (37.7)

56 (41.2)

2-3 times per week

110 (19.4)

 

27 (20.8)

51 (23.1)

19 (14.5)

13 (15.5)

111 (19.4)

 

34 (18.9)

58 (22.6)

19 (14.0)

4 or more times per week

29 (5.1)

 

6 (4.6)

6 (2.7)

9 (6.9)

8 (9.5)

29 (5.1)

 

11 (6.1)

9 (3.5)

9 (6.6)

Pre-operative smoker

121 (21.3)

-

22 (16.9)

48 (21.7)

30 (22.9)

21 (24.7)

121 (21.1)

-

33 (18.2)

57 (22.2)

31 (22.8)

Smoker at any visit

129 (22.8)

-

23 (17.7)

51 (23.1)

32 (24.4)

23 (27.1)

130 (22.6)

-

36 (19.9)

60 (23.3)

34 (25.0)

Pre-operative use of antidepressants

56 (9.9)

-

14 (10.8)

21 (9.5)

16 (12.2)

5 (5.9)

57 (9.9)

-

18 (9.9)

23 (8.9)

16 (11.8)

Ever use of HRT, %

263 (46.5)

1

54 (41.9)

102 (46.2)

70 (53.4)

37 (43.5)

267 (46.6)

1

77 (42.8)

118 (45.9)

72 (52.9)

Screening detected tumor

289 (60.3)

88b

59 (56.7)

102 (54.8)

78 (68.4)

50 (66.7)

293 (60.5)

90b

84 (56.8)

129 (59.2)

80 (67.8)

  1. *9 patients lacked genotype information.
  2. **2 patients lacked genotype information.
  3. ***IQR Interquartile range.
  4. aAnalysis included women who had not gone through breast surgery before diagnosis.
  5. bAnalysis included women 45–74 years at diagnosis due to previous Swedish screening protocols.